Dear Readers,
This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution products to firms seeking approval to market generic versions. The contributing authors ask some relevant questions such as — under w
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.140.185.147
Please verify email or join us to access premium content!